Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Innovative Trial Designs Are 'Life And Death Matter' For Pharma, Amgen Tells US FDA

Executive Summary

Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.

You may also be interested in...



Industry Calls For US FDA Transparency On Use Of Innovative Clinical Trial Designs

BIO and PhRMA ask agency to provide more guidance on trial implementation, data integrity and novel data sources.

PDUFA VII: Will Gene Therapy's Rise Influence Talks?

The Center for Biologics Evaluation and Research may need more fee revenue to add employees to handle the increasing cell and gene therapy workload.

Amgen's Elliott Levy On Adaptive Design And Real-World Evidence Strategies

Levy, SVP of global development, notes that two years after launching an in-house Center for Design and Analysis, Amgen considers adaptive designs for most new studies and more than half include adaptive elements.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel